Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Host interferon-related signaling pathways and HIV-1 LTR-dependent transcription machinery represent a complex regulatory network that governs the life cycle and persistence of HIV-1. The HIV-1 Long Terminal Repeat (LTR) functions as the viral promoter, utilizing host transcription factors like NF-κB and the P-TEFb complex to drive the expression of viral genes (Karn & Stoltzfus, 2012). This process is significantly modulated by host interferon (IFN) signaling, primarily through the JAK-STAT pathway, which can induce an antiviral state or contribute to the establishment of viral latency (Doitsh & Greene, 2016). In chronic HIV infection, persistent IFN signaling is associated with immune exhaustion and the maintenance of the latent reservoir. Therapeutic strategies targeting this machinery include the use of JAK inhibitors, such as ruxolitinib, to dampen inflammation and potentially reduce the size of the viral reservoir (Gavegnano et al., 2017). Additionally, latency-reversing agents (LRAs) aim to exploit these transcriptional pathways to shock latent viruses out of hiding for immune clearance. Consequently, this system is a focal point for research into HIV cure strategies, balancing the induction of viral expression with the control of host immune responses. Understanding the interplay between these host pathways and the viral transcription machinery is critical for developing strategies to eradicate the latent HIV reservoir (Bosque & Planelles, 2011).
Modulation of host signaling cascades and transcriptional machinery to regulate HIV-1 proviral expression and latency.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host interferon-related signaling pathways and HIV-1 LTR-dependent transcription machinery.